Predicting epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) patients through logistic regression: a model incorporating clinical characteristics, computed tomography (CT) imaging features, and tumor marker levels
PeerJ · 2024
DOI: 10.7717/peerj.18618 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, 2024. Verfasst von Jimin Hao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Sleep Medicine, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Lung Neoplasms, Tomography, X-Ray Computed. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Approximately 60% of Asian populations with non-small cell lung cancer (NSCLC) harbor epidermal growth factor receptor (EGFR) gene mutations, marking it as a pivotal target for genotype-directed therapies. Currently, determining EGFR mutation status relies on DNA sequencing of histological or cytological specimens. This study presents a predictive model integrating clinical parameters, computed tomography (CT) characteristics, and serum tumor markers to forecast EGFR mutation status in NSCLC patients.
Methods
Retrospective data collection was conducted on NSCLC patients diagnosed between January 2018 and June 2019 at the First Affiliated Hospital of Zhengzhou University, with available molecular pathology results. Clinical information, CT imaging features, and serum tumor marker levels were compiled. Four distinct models were employed in constructing the diagnostic model. Model diagnostic efficacy was assessed through receiver operating characteristic (ROC) area under the curve (AUC) values and calibration curves. DeLong’s test was administered to validate model robustness.
Results
Our study encompassed 748 participants. Logistic regression modeling, trained with the aforementioned variables, demonstrated remarkable predictive capability, achieving an AUC of 0.805 (95% confidence interval (CI) [0.766–0.844]) in the primary cohort and 0.753 (95% CI [0.687–0.818]) in the validation cohort. Calibration plots suggested a favorable fit of the model to the data.
Conclusions
The developed logistic regression model emerges as a promising tool for forecasting EGFR mutation status. It holds potential to aid clinicians in more precisely identifying patients likely to benefit from EGFR molecular testing and facilitating targeted therapy decision-making, particularly in scenarios where molecular testing is impractical or inaccessible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Sleep Medicine, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, China.
- Henan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, Henan, China.
- Laboratory of Molecular Biology, Henan Luoyang Orthopedic Hospital (Henan Provincial Orthopedic Hospital), Zhengzhou, Henan, China.
- Department of Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Hao, J., Liu, M., Zhou, Z., Zhao, C., Dai, L., & Ouyang, S. (2024). Predicting epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) patients through logistic regression: a model incorporating clinical characteristics, computed tomography (CT) imaging features, and tumor marker levels. PeerJ. https://doi.org/10.7717/peerj.18618
Vancouver
Hao J, Liu M, Zhou Z, Zhao C, Dai L, Ouyang S. Predicting epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) patients through logistic regression: a model incorporating clinical characteristics, computed tomography (CT) imaging features, and tumor marker levels. PeerJ. 2024. doi:10.7717/peerj.18618
BibTeX
@article{Hao2024,
author = {Hao, Jimin and Liu, Man and Zhou, Zhigang and Zhao, Chunling and Dai, Liping and Ouyang, Songyun},
title = {Predicting epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) patients through logistic regression: a model incorporating clinical characteristics, computed tomography (CT) imaging features, and tumor marker levels},
journal = {PeerJ},
year = {2024},
doi = {10.7717/peerj.18618}
}
EUVIMED